Segmental Reporting (by Segment) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 31, 2013		Mar. 31, 2012		Dec. 31, 2012
Segment reporting, operating income/(loss)
Product sales	$ 1,116.7		$ 1,106.9
Royalties	38.5		56.3
Other revenues	6.7		8.6
Total revenues	1,161.9		1,171.8
Cost of product sales	155.9	[1]	158.4	[1]
Research and development	224.2	[1]	220.3	[1]
Selling, general and administrative	438.7	[1]	500.0	[1]
Goodwill Impairment charge	198.9		0
Gain on sale of product rights	(6.5)		(7.2)
Reorganization costs	17.5		0
Integration and acquisition costs	4.10		5.30
Total operating expenses	1,032.8		876.8
Operating income/(loss)	129.1		295.0
Assets	7,585.6		6,718.3		7,317.2
Long-lived assets	953.9		923.3
Capital expenditure on long-lived assets	38.1		17.5
Segment reporting, additional information
Amortization of intangible assets	45.9		45.8
Cost of Product Sales
Segment reporting, additional information
Depreciation from manufacturing plants	7.8		7.2
Selling, General and Administrative
Segment reporting, additional information
Other depreciation and amortization	62.6		59.2
Favorable Manufacturing Contract | Cost of Product Sales
Segment reporting, additional information
Other depreciation and amortization			0.2
Research and Development Assets | Research and Development
Segment reporting, additional information
Depreciation from manufacturing plants	4.6		6.4
Specialty Pharmaceuticals
Segment reporting, operating income/(loss)
Product sales	746.6		706.7
Royalties	25.5		42.4
Other revenues	6.5		8.3
Total revenues	778.6		757.4
Cost of product sales	85.8	[2]	87.1	[3]
Research and development	147.4	[2]	131.0	[3]
Selling, general and administrative	257.7	[2]	300.1	[3]
Goodwill Impairment charge	0
Gain on sale of product rights	(6.5)		(7.2)
Reorganization costs	0
Integration and acquisition costs	2.00		1.60
Total operating expenses	486.4		512.6
Operating income/(loss)	292.2		244.8
Assets	2,388.7		2,463.3
Long-lived assets	125.8	[4]	126.3	[5]
Capital expenditure on long-lived assets	12.6	[4]	2.1	[5]
Human Genetic Therapies
Segment reporting, operating income/(loss)
Product sales	351.6		351.4
Royalties	0		0
Other revenues	0.2		0.3
Total revenues	351.8		351.7
Cost of product sales	61.6	[2]	61.3	[3]
Research and development	69.6	[2]	86.3	[3]
Selling, general and administrative	105.6	[2]	104.4	[3]
Goodwill Impairment charge	0
Gain on sale of product rights	0		0
Reorganization costs	0
Integration and acquisition costs	1.30		0
Total operating expenses	238.1		252.0
Operating income/(loss)	113.7		99.7
Assets	2,200.7		1,917.9
Long-lived assets	691.0	[4]	712.1	[5]
Capital expenditure on long-lived assets	9.3	[4]	13.0	[5]
Regenerative Medicine
Segment reporting, operating income/(loss)
Product sales	18.5		48.8
Royalties	0		0
Other revenues	0		0
Total revenues	18.5		48.8
Cost of product sales	8.5	[2]	10.0	[3]
Research and development	7.2	[2]	3.0	[3]
Selling, general and administrative	47.8	[2]	41.7	[3]
Goodwill Impairment charge	198.9
Gain on sale of product rights	0		0
Reorganization costs	0
Integration and acquisition costs	0.80		3.70
Total operating expenses	263.2		58.4
Operating income/(loss)	(244.7)		(9.6)
Assets	946.9		961.5
Long-lived assets	44.3	[4]	23.2	[5]
Capital expenditure on long-lived assets	9.3	[4]	0.1	[5]
All Other Segment
Segment reporting, operating income/(loss)
Product sales	0		0
Royalties	13.0		13.9
Other revenues	0		0
Total revenues	13.0		13.9
Cost of product sales	0	[2]	0	[3]
Research and development	0	[2]	0	[3]
Selling, general and administrative	27.6	[2]	53.8	[3]
Goodwill Impairment charge
Gain on sale of product rights	0		0
Reorganization costs	17.5
Integration and acquisition costs			0
Total operating expenses	45.1		53.8
Operating income/(loss)	(32.1)		(39.9)
Assets	2,049.3		1,375.6
Long-lived assets	92.8	[4]	61.7	[5]
Capital expenditure on long-lived assets	$ 6.9	[4]	$ 2.3	[5]

[1] Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $nil for the three months to March 31, 2013 (2012: $0.2 million). SG&A costs includes amortization of intangible assets relating to intellectual property rights acquired of $45.9 million for the three months to March 31, 2013 (2012: $45.6 million).

[2] (1) Depreciation from manufacturing plants ($7.8 million) is included in Cost of product sales; depreciation of research and development assets ($4.6 million) is included in Research and development; and all other depreciation and amortization ($62.6 million) is included in Selling, general and administrative.

[3] (1) Depreciation from manufacturing plants ($7.2 million) and amortization of favorable manufacturing contracts ($0.2 million) is included in Cost of product sales; depreciation of research and development assets ($6.4 million) is included in Research and development; and all other depreciation, amortization and impairment charges ($59.2 million) is included in Selling, general and administrative.

[4] (2) Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments)

[5] (2) Long-lived assets comprise all non-current assets (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments, income tax receivable and financial instruments).